Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

PARIET 20 MG COMPRIMIDOS GASTRORRESISTENTES - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/PARIET 20 MG COMPRIMIDOS GASTRORRESISTENTES

Approved

STANDARD

PARIET 20 MG COMPRIMIDOS GASTRORRESISTENTES

Janssen Cilag S.P.A.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 14, 2024
Approval ID: 5530c5e3052c10f0
Company: Janssen Cilag S.P.A.
Type: Standard

Approval Details

Approval Id: 5530c5e3052c10f0
Drug Cima Aemps Name: PARIET 20 MG COMPRIMIDOS GASTRORRESISTENTES
Register Number: 034216186
Holder Company Name: Janssen Cilag S.P.A.
Marketing Company Name: Melyfarma S.L.
Authorization Date: 2024-06-14
Dosage Form: COMPRIMIDO GASTRORRESISTENTE
Dose: 20 mg
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: Yes
Company Name: Janssen Cilag S.P.A.

Active Ingredients

RABEPRAZOL SODICO

20 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 14, 2024

Approval ID

5530c5e3052c10f0

Type

Standard

Back to CIMA-AEMPS Approvals